Get your free ETF data sample from our comprehensive offerings. Start your free trial→

Help us improve your experience. Please confirm your investor type:

Global ETF Survey 2026

The ETF Industry Is Evolving Fast

From AI infrastructure to active strategies, the ETF landscape is shifting. Share your perspective in the 7th Annual Global ETF Survey.

Take the survey

›ETF Issuers›First Trust›FBT

FBT

First Trust NYSE Arca Biotechnology ETF

Passive ETF Equity

Not rated

The FBT Exchange Traded Fund (ETF) is provided by First Trust. It is built to track an index: NYSE Arca Biotechnology Index. This share class generates a stream of income by distributing dividends.

$43.54

-$0.3 (-0.68%) today

2:34 PM 07/14/26 Open

1D price range

$43.54$43.54

52W price range

$27.49$45.76

YTD Perf.

+23.51%

YTD Flows

Annualized volatility

Fund AuM

€3.8M

Share class AuM

€3.8M

TTM Yield

Tracking Error

Tracking Difference

Characteristics

ISIN

CA33742D1050

TER

0.71%

Inception date

10/30/2014

Issuer

First Trust

Benchmark

NYSE Arca Biotechnology Index

Replication method

Dividend policy

Distributing

Compare similar ETFs

ETF Name	1w perf.
FBT First Trust NYSE Arca Biotechnology Index Fund ETF	-2.35%
FBT First Trust NYSE Arca Biotechnology UCITS ETF	-3.14%
PBE Invesco Dynamic Biotechnology & Genome ETF	-1.43%
EKG First Trust Nasdaq Lux Digital Health Solutions ETF	-1.48%
CURE VanEck Genomics and Healthcare Innovators UCITS ETF	-4.91%
IHI iShares U.S. Medical Devices ETF	-1.48%
DOCG L&G Healthcare Technology & Innovation UCITS ETF	-2.24%
HTEC Robo Global Healthcare Technology and Innovation ETF	-1.98%
BTEC iShares Nasdaq US Biotechnology UCITS ETF	-2.94%
IBBQ Invesco Nasdaq Biotechnology ETF	-2.94%
203780 Mirae Asset TIGER NASDAQ BIO ETF	-3.52%
00678 CAPITAL NASDAQ BIOTECHNOLOGY INDEX ETF	+4.21%
XHE State Street SPDR S&P Health Care Equipment ETF	-0.77%
HELX Franklin Genomic Advancements ETF	-2.29%
IBB iShares Biotechnology ETF	-2.93%

API

PerformanceDec 31, 2025 - Jul 13, 2026

Flows

Join for free to unlock

Sector exposures

Data as of 05/31/26

Healthcare

99.94%

Latest FBT news

No content available for this fund

FAQ about FBT

FBT is a Passive ETF. This ETF provides exposure to Equally Weighted US Biotechnology Equities.

FBT tracks the NYSE Arca Biotechnology Total Return Index - USD, through a replication method.

FBT carries a total expense ratio (TER) of 0.71%, indicating the annual cost for holding the fund.

FBT was introduced to the market on October 30, 2014. It trades on Canada

First Trust NYSE Arca Biotechnology ETF, FBT, is provided by First Trust. Learn more about First Trust here.

FBT oversees €3.8M in assets as of July 13, 2026.

FBT follows a distributing dividend policy, meaning it pays out income to investors.

As of May 31, 2026, FBT has significant geographic allocations in USA, Ireland and Netherlands.

As of May 31, 2026, FBT focuses largely on Healthcare.

As of May 31, 2026, FBT holds 30 positions in its portfolio, with 57.82% of assets concentrated in its top 15 holdings.

As of May 31, 2026, FBT top three holdings include Corcept Therapeutics, Inc., Bruker Corp. and Veracyte, Inc..

The base currency of FBT is CAD.

Top 10 holdings

Data as of 05/31/26

Corcept Therapeutics, Inc.

5.10%

Bruker Corp.

4.71%

Veracyte, Inc.

4.70%

Illumina, Inc.

4.12%

NeoGenomics, Inc.

4.12%

Axsome Therapeutics, Inc.

3.92%

Alkermes Plc

3.84%

Neurocrine Biosciences, Inc.

3.79%

Arrowhead Pharmaceuticals, Inc.

3.50%

Krystal Biotech, Inc.

3.49%

Essentials

A forever free toolbox for fund selection, analysis, research, and ETF portfolio construction.

Essential free account includes:

More fund data
Compare up to 3 funds
More screener filters
Edit screener columns from 100+ metrics
Watchlists for saving your research
Portfolio construction and analysis
Personal dashboard for live monitoring

About Trackinsight

Since our founding in 2016, we have been at the forefront of the industry, delivering accessible, comprehensive, and reliable tools to support the evolving needs of investors.

Over the past decade, Trackinsight has expanded its operations across six countries, serving thousands of professional investors. We’ve consistently innovated to provide cutting-edge solutions that meet the changing demands of the ETF market.

In 2024, Kepler Cheuvreux, a leading independent European financial services firm, acquired a majority stake in Trackinsight, becoming the company's principal shareholder.

This strategic partnership solidifies Trackinsight's position as a premier provider of ETF selection and analysis tools, while strengthening Kepler Cheuvreux’s commitment to becoming a leading player in the ETF sector.

Together, we are committed to offering advanced services that empower professional investors, advisors, institutions, and issuers. This new step enables us to deliver even more comprehensive and innovative technological solutions, driving ETF investing to new heights.

More about Trackinsight

The ETF Industry Is Evolving Fast

First Trust NYSE Arca Biotechnology ETF

FAQ about FBT

Essentials

About Trackinsight

ETF TOOLS

PLATFORM

ETF NEWS & RESEARCH

PROFESSIONAL SOLUTIONS

SOLUTIONS FOR

CONTACT US